EXCLUSIVE LICENSE AGREEMENT BioAtla Holdings LLC and BioAtla LLCExclusive License Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • California
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is entered into as of January 1, 2020, (the “Execution Date”), by and between BIOATLA HOLDINGS LLC, a Delaware corporation (the “Company”), and BIOATLA LLC, a Delaware limited liability company, having an address of 11085 Torreyana Road, San Diego, California 92121, USA (“BioAtla”).
ROYALTY SHARING AGREEMENTRoyalty Sharing Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • California
This Royalty Sharing Agreement (this “Agreement”) is made and entered into as of January 1, 2020 by and between BioAtla, LLC, a Delaware limited liability company (“BioAtla”), and BioAtla Holdings, LLC, a Delaware limited liability company (“Holdings”).
EXCLUSIVE RIGHTS AGREEMENTExclusive Rights Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED EXCLUSIVE RIGHTS AGREEMENT (the “Agreement”) is effective January 1st, 2020 (the “Effective Date”) by and between BioAtla LLC, a Delaware limited liability company (“BioAtla”), Himalaya Therapeutics SEZC (formerly named BioAtla Cayman SEZC), a company organized under the laws of the Cayman Islands, having a registered office c/o International Corporation Services Ltd., P.O. Box 472, Harbour Place, 2nd Floor, 103 South Church Street, George Town, Grand Cayman KY1-1106, Cayman Islands, and Himalaya Therapeutics Hong Kong (formerly BioAtla Hong Kong Holding), having offices at 6th Floor, Alexandra House 18 Chater Road, Central Hong Kong (collectively, “Himalaya”).
LIFE TECHNOLOGIES [***] CELL LINE LICENSE AGREEMENTCell Line License Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • California
This [***] CELL LINE LICENSE AGREEMENT (the “AGREEMENT”), is entered Into and made effective as of June 28 2018 (the “EFFECTIVE DATE”), by and between Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific Inc., having its principal place of business at 5823 Newton Drive, Carlsbad, CA 92008 USA (“LIFE”), and the following organization, organized under the laws of the indicated state or jurisdiction, and having its principal place of business at the indicated address as follows:
GLOBAL CO-DEVELOPMENT AND COLLABORATION AGREEMENT by and among BioAtla, LLC, BeiGene, Ltd. and BeiGene Switzerland GmbH Dated as of April 8, 2019Global Co-Development and Collaboration Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • New York
This Global Co-Development and Collaboration Agreement (this “Agreement”) is entered into as of April 8, 2019 (the “Effective Date”), by and among BioAtla, LLC, a Delaware limited liability company (“BioAtla”), BeiGene, Ltd., a Cayman Islands corporation (“BeiGene Cayman”) and BeiGene Switzerland GmbH, a company organized under the laws of Switzerland having an address of c/o VISCHER AG, Aeschenvorstadt 4, 4051 Basel, Switzerland (“BeiGene Switzerland” and together with BeiGene Cayman and its Affiliates, collectively, “BeiGene”). BeiGene and BioAtla are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT INVERSAGEN LLC AND BIOATLA, LLCExclusive License Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • California
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is entered into as of March 15, 2019 (the “Execution Date”), by and between INVERSAGEN LLC, a Delaware limited liability company, (the “Company”), and BIOATLA, LLC, a Delaware limited liability company (“BioAtla”).
